Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: a rapid review and meta‐analysis
This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …
Efficacy and safety of sotrovimab in patients with COVID‐19: A rapid review and meta‐analysis
The therapeutic potential of sotrovimab in the treatment of coronavirus disease 2019 (COVID‐
19) is a controversial issue. The aim of this study was to evaluate the efficacy and safety of …
19) is a controversial issue. The aim of this study was to evaluate the efficacy and safety of …
[HTML][HTML] COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA. 1 era
J Hedvat, NW Lange, DM Salerno… - American Journal of …, 2022 - Elsevier
Treatment outcomes associated with the use of novel COVID-19 therapeutics in solid organ
transplant recipients (SOTR) are not well described in the literature. The objective of this …
transplant recipients (SOTR) are not well described in the literature. The objective of this …
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales …
A Evans, C Qi, JO Adebayo, J Underwood, J Coulson… - Journal of Infection, 2023 - Elsevier
Objective To compare the effectiveness of molnupiravir, nirmatrelvir-ritonavir, and
sotrovimab with no treatment in preventing hospital admission or death in higher-risk …
sotrovimab with no treatment in preventing hospital admission or death in higher-risk …
Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID‐19: A systematic review and meta‐analysis
This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled …
MG Johnson, JM Strizki, ML Brown, H Wan… - Infection, 2023 - Springer
Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …
Clinical efficacy of anti‐SARS‐CoV‐2 monoclonal antibodies in preventing hospitalisation and mortality among patients infected with Omicron variants: A systematic …
D Miljanovic, A Cirkovic, I Lazarevic… - Reviews in Medical …, 2023 - Wiley Online Library
Until now, the treatment protocols for COVID‐19 have been revised multiple times. The use
and approval of therapeutic monoclonal antibodies (mAbs) for COVID‐19 treatment …
and approval of therapeutic monoclonal antibodies (mAbs) for COVID‐19 treatment …
Preliminary clinical experience of molnupiravir to prevent progression of COVID-19 in kidney transplant recipients
M Villamarín, E Márquez-Algaba, J Esperalba… - …, 2022 - journals.lww.com
Background. Recently, different therapeutic lines have been tried in the initial stage of the
disease of COVID-19, including remdesivir and molnupiravir. There is scarce evidence on …
disease of COVID-19, including remdesivir and molnupiravir. There is scarce evidence on …
Molnupiravir when used alone seems to be safe and effective as outpatient COVID-19 therapy for hemodialyzed patients and kidney transplant recipients
P Poznański, H Augustyniak-Bartosik, A Magiera-Żak… - Viruses, 2022 - mdpi.com
Background: Molnupiravir demonstrated an in vitro antiviral activity against positive-sense
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …
RNA viruses, including SARS-CoV-2. The study aimed to present the results of outpatient …
What is the efficacy of sotrovimab in reducing disease progression and death in people with COVID-19 during the omicron era? Answers from a real-life study
A De Vito, A Colpani, M Poliseno, L Diella, FRP Ieva… - Viruses, 2023 - mdpi.com
(1) Introduction: Since May 2021, sotrovimab has been available in Italy for early treatment
of SARS-CoV-2 infection and to prevent disease progression. However, some in vitro …
of SARS-CoV-2 infection and to prevent disease progression. However, some in vitro …